Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
Bioorg Med Chem Lett. 2020 Dec 1;30(23):127538. doi: 10.1016/j.bmcl.2020.127538. Epub 2020 Sep 11.
Direct inhibition of GPX4 requires covalent modification of the active-site selenocysteine. While phenotypic screening has revealed that activated alkyl chlorides and masked nitrile oxides can inhibit GPX4 covalently, a systematic assessment of potential electrophilic warheads with the capacity to inhibit cellular GPX4 has been lacking. Here, we survey more than 25 electrophilic warheads across several distinct GPX4-targeting scaffolds. We find that electrophiles with attenuated reactivity compared to chloroacetamides are unable to inhibit GPX4 despite the expected nucleophilicity of the selenocysteine residue. However, highly reactive propiolamides we uncover in this study can substitute for chloroacetamide and nitroisoxazole warheads in GPX4 inhibitors. Our observations suggest that electrophile masking strategies, including those we describe for propiolamide- and nitrile-oxide-based warheads, may be promising for the development of improved covalent GPX4 inhibitors.
直接抑制 GPX4 需要对活性位点硒半胱氨酸进行共价修饰。虽然表型筛选已经揭示了激活的烷基氯和掩蔽的腈氧化物可以共价抑制 GPX4,但缺乏对具有抑制细胞 GPX4 能力的潜在亲电弹头的系统评估。在这里,我们调查了超过 25 种亲电弹头,涉及几个不同的 GPX4 靶向支架。我们发现,与氯乙酰胺相比,反应性减弱的亲电试剂尽管硒半胱氨酸残基具有预期的亲核性,但无法抑制 GPX4。然而,我们在这项研究中发现的高反应性丙烯酰胺可以替代 GPX4 抑制剂中的氯乙酰胺和硝基异唑弹头。我们的观察结果表明,亲电试剂掩蔽策略,包括我们为丙烯酰胺和腈氧化物基弹头描述的那些,可能是开发改进的共价 GPX4 抑制剂的有前途的方法。